Chronic bronchitis, pneumonia, emphysema linked to lung cancer risk
the ONA take:
According to a new study published in the American Journal of Respiratory and Critical Care Medicine, three common respiratory diseases, chronic bronchitis, emphysema, and pneumonia, were associated with a higher risk of developing lung cancer. The study also found that asthma and tuberculosis were not linked with an increased risk.
The researchers analyzed data from seven studies and found that patients who had chronic bronchitis, emphysema, and pneumonia had an increased risk of lung cancer compared with who only had chronic bronchitis.
They also found that those who had asthma, chronic bronchitis, and tuberculosis, did not have an increased risk. Study author Ann Olsson, RN, MPH, PhD, said that underlying disease mechanisms may affect the risk of developing lung cancer in different ways. Despite the association found in this study, a cause-and-effect relationship between respiratory diseases and increased lung cancer risk was not proven.
Chronic bronchitis, emphysema, pneumonia, and lung cancer are oftentimes associated with smoking cigarettes. It is unclear yet if this study accounted for smokers. Patients should be counseled on the dangerous effects of smoking cigarettes and their association with many disease states.
Three common respiratory diseases seem to be associated with an increased risk of lung cancer.
Three common respiratory diseases seem to be associated with an increased risk of lung cancer, researchers report.
The investigators analyzed data from seven studies that included more than 25,000 people and found that chronic bronchitis, emphysema and pneumonia were linked with a greater risk of developing lung cancer.
Having asthma or tuberculosis was not associated with a higher lung cancer risk, according to the study published in the Aug. 15 issue of the American Journal of Respiratory and Critical Care Medicine.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|